All In Biotech

Free tool

FAERS Monitor: Xuriden

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208169 or its brand name (Xuriden, Uridine Triacetate). Reports on generic versions are filed under their own applications.

Reports

48

Serious

28

58% of reports

Hospitalization

17

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use11
  • diarrhoea4
  • foetal exposure during pregnancy4
  • low birth weight baby4
  • mucosal inflammation4
  • premature baby4
  • thrombocytopenia4
  • asthenia3
  • drug ineffective3
  • drug ineffective for unapproved indication3
  • dysphagia3
  • gastroenteritis3
  • neutropenia3
  • neutropenic colitis3
  • stomatitis3

Reports by year received

View as table
YearReports
20141
20165
20176
20182
20195
20204
20216
20221
20231
20243
20257
20267

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,111 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
neutropenic colitisSignal3636.6212.61,319
low birth weight babySignal4220.786.3669
gastroenteritisSignal390.130.1183
mucosal inflammationSignal467.026.2198
premature babySignal458.222.8172
drug ineffective for unapproved indicationSignal324.08.045
stomatitisSignal321.77.240
foetal exposure during pregnancySignal421.68.459
thrombocytopeniaSignal415.76.141
dysphagiaSignal313.84.624
neutropeniaSignal39.73.216
off label useSignal115.53.338
asthenia33.51.23
diarrhoea42.71.13
drug ineffective31.00.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.